Delivering Hope in Ovarian Cancer
News Aug 11, 2015
Using gene therapy to deliver a protein that suppresses the development of female reproductive organs may improve the survival of patients with ovarian cancer that has recurred after chemotherapy. Recurrence happens 70 percent of the time and is invariably fatal.
In their report, Harvard Medical School researchers at Massachusetts General Hospital describe how a single injection of a modified version of Mullerian Inhibiting Substance, a protein critical to sexual development, suppressed the growth of chemotherapy-resistant ovarian tumors in a mouse model.
While not all the tested tumors, which were grown from cells grafted from patient tumors, were sensitive to this treatment, the investigators also outlined a noninvasive way to screen cancer cells in vitro for treatment responsiveness.
“Our findings are important because there are currently no therapeutic options for recurrent, chemoresistant ovarian cancer,” said David Pépin, HMS instructor in surgery at Mass General and lead author of the report. “This is also a proof of concept that gene therapies with the AAV9 vector can be used to deliver biologics for the treatment of ovarian cancer and represents the first time this approach has been tested in this type of ovarian cancer model.”
Potential to treat cancer
During embryonic development, Mullerian Inhibiting Substance is secreted by tissues in male embryos to prevent maturation of the Mullerian duct, which otherwise would give rise to female reproductive organs. The potential of MIS to treat ovarian cancer and other reproductive tumors has been studied for many years by Patricia Donahoe, Marshall K. Bartlett Distinguished Professor of Surgery at HMS, director of Mass General’s Pediatric Surgical Research Laboratories and senior author of the current study.
Previous investigations by Donahoe’s team showed that MIS suppresses ovarian cancer growth, both in animals and in human cell lines, by targeting the cancer stem cells that survive chemotherapy. But previous methods of producing MIS were unable to generate sufficient quantities of high-quality protein for pre-clinical testing.
The current study employed a modified form of the MIS gene, developed by Pépin to generate proteins of greater purity and effectiveness, combined with the accepted viral vector AAV9 for delivery into the peritoneal cavity, a common site for the recurrence of ovarian cancer. The modified MIS/AAV9 construct was tested against tumor cells taken from ascites fluid that had accumulated within the abdomens of several patients with recurrent ovarian cancer.
Initial experiments confirmed that these cells expressed the MIS receptor protein, that they carried markers indicating their identity as cancer stem cells, and that their growth was inhibited in vitro by MIS. A single injection of the MIS/AAV9 construct into the peritoneal cavity of mice resulted in elevated expression of MIS by multiple tissues throughout the abdominal cavity and in adjacent muscles.
The effectiveness of the MIS/AAV9 construct was tested in mice into which ovarian cancer cells were implanted. Those efforts revealed that treatment with MIS/AAV9 three weeks before tumor implantation significantly inhibited tumor growth.
In a more clinically relevant experiment, the therapy was applied to mice in which tumors already had been induced by implantation of cancer cells from five different patients. The therapy resulted in significant inhibition of further growth of tumors generated from the cells of three of the five patients.
Analysis of tumor samples from more than 200 patients revealed that 88 percent expressed some level of the MIS receptor, with 65 percent expressing moderate or high protein expression.
Need for biomarkers
“Since the response to MIS gene therapy is not the same for all patients, it will be important to first screen each patient’s tumors to ensure they will respond” said Pépin. “While we have not yet identified biomarkers of treatment response—something we are currently searching for—we have described a way to rapidly grow tumor cells from ascites to be evaluated for drug sensitivity. If further study confirms the susceptibility of chemoresistant tumors to this MIS gene therapy, the ability to inhibit tumor recurrence could significantly extend patient survival.”
The MIS/AAV9 construct was prepared by Guangping Gao, director of the Gene Therapy Center at the University of Massachusetts Medical School. The single, long-acting injection makes the use of this effective but complex protein both clinically feasible and patient friendly, Donahoe said.
“All of the implanted tumor cells were from patients who failed all previous therapies, so a 60 percent response rate is quite significant for a single agent,” said Donahoe. “Our results provide proof of concept and predict a translation into patient care that was not previously possible.”
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
Improved Capture of Free-Floating Cancer Cells, Cast-Off from TumorsNews
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center and University of Wisconsin-Madison have demonstrated improved methods of capturing free-floating cancer cells that are cast-off from tumors, and circulating in the blood.READ MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE